TVAX Biomedical

G. Yancey Gillespie III, Ph.D. Cancer immunologist. Professor of Surgery, Microbiology and Cell Biology/Anatomy, University of Alabama at Birmingham. Director of the Brain Tumor Research Laboratories in the University of Alabama at Birmingham’s Comprehensive Cancer Research Center.  Author of over 120 journal articles and book chapters on brain cancer and cancer immunology. Member, scientific advisory boards of Novapharm Biotech, Ltd, NeuroVir Therapeutics Inc./Medigene, Inc., Targepeutics, Inc., Ceregene, Inc. and SunBiochem, Inc. [Ph.D., M.S., B.A., University of Mississippi].

Barry S. Skikne, M.D. Hematologist/oncologist. Associate Medical Director, Celgene Pharmaceuticals from 2008 to present. Hematologist/oncologist, Professor of Internal Medicine and Director, Bone Marrow Transplantation Program in the KU Cancer Center at the University of Kansas Medical Center until 2008. Author of more than ninety journal articles and book chapters. [M.B.B.Ch., E.C.F.M.G., University of Witwatersrand, Johannesburg, SA. F.C.P.[S.A.], College of Physicians of South Africa].

Andrew E. Sloan M.D., F.A.C.S. Neurosurgeon. Associate Professor of Neurological Surgery, Case Western Reserve University.   Dr. Sloan was the Principal Investigator of the most recent phase II brain cancer clinical trial of TVAX Immunotherapy.  [Neurosurgical Oncology Fellowship, M.D. Anderson Cancer Center; Neurosurgical Residency, UCLA; M.D., Harvard; B.S., Yale].

J. Brantley Thrasher, M.D. Chairman, Department of Urological Surgery, KU Medical Center. Valk Professor of Urological Surgery. Author of over 100 journal articles and book chapters. Member, Executive Board of the Society of Urologic Oncology. Member, American Joint Committee on Cancer. Urologic Oncology Fellowship, Duke University; Urology Residency, Fitzsimons Army Medical Center; M.D., Medical University of South Carolina; B.S. (Summa Cum Laude), Clemson University.

Lowell Tilzer, M.D., Ph.D.  Chairman, Department of Pathology and Medical Director, Clinical Laboratories, the University of Kansas Medical Center.  Dr. Tilzer is a clinical pathologist, is an expert in blood processing and has over ten years of direct experience in working with the FDA. Dr. Tilzer has held a series of senior management positions within the Blood Services division of the American Red Cross, including service as Chief Executive Officer of the American Red Cross Southwest Region and, prior to that, held senior management positions with the Community Blood Center of Kansas City and the Community Blood Center of the Ozarks. B.A. University of Kansas; M.D., Ph.D. and Pathology Residency, the University of Kansas Medical Center.

Return to Home Page